Wendell David Associates Inc. Decreases Stake in Pfizer Inc. $PFE

Wendell David Associates Inc. reduced its holdings in Pfizer Inc. (NYSE:PFE) by 3.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,037 shares of the biopharmaceutical company’s stock after selling 1,820 shares during the period. Wendell David Associates Inc.’s holdings in Pfizer were worth $1,383,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. GKV Capital Management Co. Inc. acquired a new stake in Pfizer during the first quarter worth about $27,000. Bayforest Capital Ltd acquired a new stake in shares of Pfizer during the first quarter valued at about $28,000. North Capital Inc. acquired a new stake in shares of Pfizer during the first quarter valued at about $28,000. Harbor Asset Planning Inc. acquired a new stake in shares of Pfizer during the second quarter valued at about $29,000. Finally, WPG Advisers LLC acquired a new stake in shares of Pfizer during the first quarter valued at about $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Up 1.2%

Shares of NYSE:PFE opened at $24.52 on Friday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.36. The company’s 50 day moving average is $24.89 and its two-hundred day moving average is $24.11. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market cap of $139.38 billion, a PE ratio of 13.04, a P/E/G ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the prior year, the firm posted $0.60 EPS. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. Pfizer’s dividend payout ratio is currently 91.49%.

Analyst Ratings Changes

A number of brokerages recently weighed in on PFE. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. UBS Group restated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Morgan Stanley dropped their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Bank of America lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Finally, Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $28.13.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.